Endovia Health Sciences (EDVA) Net Cash Flow Growth (5y) (2017 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Net Cash Flow Growth (5y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -64.24% |
| Mar 31, 2026 | -32.61% |
| Dec 31, 2025 | 41.83% |
| Sep 30, 2025 | -20.30% |
| Jun 30, 2025 | 17.51% |
| Mar 31, 2025 | -15.89% |
| Dec 31, 2024 | 81.13% |
| Sep 30, 2024 | 62.42% |
| Jun 30, 2024 | 49.67% |
| Mar 31, 2024 | 11.60% |
| Dec 31, 2023 | 85.33% |
| Sep 30, 2023 | -135.22% |
| Jun 30, 2023 | -231.28% |
| Mar 31, 2023 | -184.97% |
| Dec 31, 2022 | 150.84% |
| Sep 30, 2022 | -126.71% |
| Jun 30, 2022 | -165.40% |
| Mar 31, 2022 | 186.98% |
| Dec 31, 2021 | -167.97% |
| Sep 30, 2021 | -335.66% |